Carella

Hagens Berman: Nation’s Prominent Plaintiff-Side Law Firms Unite Against the “Appalling Rise” of Antisemitism Across Law School and College Campuses

Retrieved on: 
Wednesday, November 15, 2023
Education, Legal, Professional Services, University, Woman, Violence, Safety, Organization, Racism, LLP, Civil Rights Act, Fraud, Baron & Budd, P.C., Student, Faculty, Mentorship, Edelson, Title 6, Rape, School, Carella, Social justice, Person, Grant & Eisenhofer, Torture, Jews, Letter, Environment, Nursing, Hamas

The leading plaintiff-side class action and civil rights firms banding together include Baron & Budd; Carella, Byrne, Cecchi, Brody & Agnello, P.C.

Key Points: 
  • The leading plaintiff-side class action and civil rights firms banding together include Baron & Budd; Carella, Byrne, Cecchi, Brody & Agnello, P.C.
  • They are sending their letter to all U.S. law schools, including dozens of schools which the firms routinely recruit and hire from.
  • We write to you on behalf of several of the largest and most successful plaintiff-side law firms in the world.
  • We ask you to ensure the safety of Jewish law students and to condemn without qualification this rising antisemitism.

DiCello Levitt: Pharmaceutical Companies Violated Consumer Protection Laws, Committed Fraud by Selling Medicine Containing Ineffective Nasal Decongestant, According to New Lawsuit

Retrieved on: 
Thursday, September 14, 2023
Class Action Lawsuit, Professional Services, Legal, LLP, GSK plc, Marketing, Pharmacy, Disclosure, Carella, Sale, Complaint, The Journal of Allergy and Clinical Immunology, District court, Journal, Procter & Gamble, Patient, Food and Drug Administration, Knowledge, Johnson & Johnson, Nasal congestion, Food, Phenylephrine, Pharmaceutical industry, Walgreens

The complaint is among the first to be filed following a Food & Drug Administration advisory panel’s unanimous finding that the ingredient, phenylephrine, is ineffective in oral medication.

Key Points: 
  • The complaint is among the first to be filed following a Food & Drug Administration advisory panel’s unanimous finding that the ingredient, phenylephrine, is ineffective in oral medication.
  • In the last year alone, nearly $1.8 billion in sales of such phenylephrine-containing purported decongestants were made in the United States across 250 products.
  • In a 2006 report published in the Journal of Allergy and Clinical Immunology, researchers found that “Phenylephrine…is unlikely to provide relief of nasal congestion.
  • A copy of the complaint is available upon request, and attorneys from DiCello Levitt are available for media interviews.

Burger Law Files Class Action Lawsuit Against Ferrari For Brake Failure

Retrieved on: 
Thursday, September 29, 2022
Safety, Defect, Law, Sale, Pressure, National Highway Traffic Safety Administration, Defendant, Fraud, PC, Ferrari, Cuneo Gilbert & LaDuca, LLP, Carella, Tobacco, Hydraulic machinery, Ridesharing company

NEWARK, N.J. , Sept. 29, 2022 /PRNewswire/ -- St. Louis-based law firm Burger Law, a law firm that specializes in product liability and class action lawsuits, is representing the plaintiff in a lawsuit against manufacturers Ferrari and Robert Bosch. The plaintiff alleges that he twice experienced sudden brake failure due to defective motor vehicle components and asserts that the vehicle and defective component manufacturers are liable. The lawsuit is a class action and may be joined by others who have sustained losses due to the defective product. It is pending in federal court in New Jersey as Case number 2:21-cv-20772-JMV-CLW, and called Rose v. Ferrari North America, Inc. To learn more or submit your information please visit our Ferrari Brake Recall page.

Key Points: 
  • Burger Law has partnered with Carella Byrne Cecchi Brody Agnello, PC and Cuneo Gilbert and LaDuca in a class action lawsuit against manufacturers Ferrari and Robert Bosch due to a product recall over possible partial or total brake failures.
  • NEWARK, N.J., Sept. 29, 2022 /PRNewswire/ -- St. Louis-based law firm Burger Law , a law firm that specializes in product liability and class action lawsuits, is representing the plaintiff in a lawsuit against manufacturers Ferrari and Robert Bosch.
  • The lawsuit is a class action and may be joined by others who have sustained losses due to the defective product.
  • Burger Law Files Class Action Lawsuit Against Ferrari and Bosch For Brake Failure.

Kessler Topaz Meltzer & Check, LLP: Bayer Corporation to Pay $40 Million to Settle Whistleblower Claims Alleging Fraud in Marketing Three Drugs

Retrieved on: 
Friday, September 2, 2022
Legal, Professional Services, Bayer Corporation, Accusative case, Office of Inspector General, U.S. Department of Health and Human Services, Safety, False Claims Act, Government, LLP, Time, Hospital, Complaint, FCA, P.C, Fraud, U.S. Department of Defense Strategy for Operating in Cyberspace, Review, Contract, Travel, Pharmaceutical industry, Aprotinin, Counsel, Bayer, Carella

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) announces today that Bayer Corporation (Bayer) has agreed to pay $40 million to resolve claims in two longstanding, whistleblower lawsuits alleging that Bayer violated anti-fraud laws in selling and promoting three drugs, Trasylol, Avelox and Baycol.

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) announces today that Bayer Corporation (Bayer) has agreed to pay $40 million to resolve claims in two longstanding, whistleblower lawsuits alleging that Bayer violated anti-fraud laws in selling and promoting three drugs, Trasylol, Avelox and Baycol.
  • In addition, Bayer agreed to pay a separate amount to resolve claims that it unlawfully retaliated against the whistleblower who raised her concerns to superiors.
  • The cases were brought under the False Claims Act by a former Bayer employee, on behalf of the United States and numerous states.
  • Kessler Topaz has represented the whistleblower since 2014, with the whistleblower and her counsel devoting extensive time and expense towards litigating these non-intervened cases.

CCNY Student-Led Start-Up Carella Wins $25,000 at Standard Chartered 2022 Women in Tech Incubator Competition

Retrieved on: 
Tuesday, May 10, 2022
Professional Services, Education, Consumer, Women, Finance, Other Education, Banking, Hope, Upwardly Global, Standard Chartered, Instagram, Twitter, Student, City College of New York, Woman, University, City, New Yorkers, College and university rankings, School, Corporate Affairs, Entrepreneurship, Partnership, Creativity, Business, Program, History, CCNY, Harvard University, Learning, Social change, City college, Center, Commerce, LinkedIn, Income, Standard, Education, Parity, CEO, Technology, Research, Mentorship, Aquaveo, Management, Carella, Facebook

The City College of New York (CCNY) Student-led start-up Carella has taken top spot at Standard Chartered Americas (Bank) 2022 Women in Tech (WiT) Incubator Competition.

Key Points: 
  • The City College of New York (CCNY) Student-led start-up Carella has taken top spot at Standard Chartered Americas (Bank) 2022 Women in Tech (WiT) Incubator Competition.
  • This year marks the eighth anniversary of the Banks partnership with the Zahn Center at CCNY.
  • We are incredibly grateful to the Zahn Center staff and Standard Chartered for the support, resources, and opportunities they have provided us."
  • Formed in October 2014, the Standard Chartered Women in Tech Incubator program is an initiative that aims to support greater diversity in gender representation within the technology sector.